ENRICH BIOSYSTEMS INC
Microgel lithography platform for high-throughput single-cell analysis and bioprocessing
- Sector
- Biotech
- Headquarters
- WORCESTER, MA
- Founded
- 2018
- Latest Form D
- $1.4M, Nov 2025
- Total capital
- $10.7M
- Federal grants
- $2.1M
- 2 awards · 2020
- Rank in peer group#1 of 18
- Private capital raised
- $8.2M
- 4 Form D · last Nov 2025
- 11 months since last filing
- Federal contracts
- $400K
- 1 award · Health and Human S
- Rank in Biotech#244 of 4373
- Granted patents
- 1
- 3 pending · first 2025
- Rank in peer group#4 of 18
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$1.4M
- Private capital raisedForm D · SEC · 3rd filing$2.2M
- Private capital raisedForm D · SEC · 2nd filing$750K
- Federal contractHealth and Human S · SBIR Phase I Topic #439 - Advanced Sample Processing Platforms For Downstream Single-cell Multi-omic Analysis$400K
- Private capital raisedForm D · SEC · 1st filing$3.8M
- Federal grantHealth and Human S · Phase II · Single clone discovery using an image-based cell isolation platform$1.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Federal first
22months
from ENRICH BIOSYSTEMS INC’s first federal award to its first private round.
- First federal award · Aug 2020
- Health and Human S · $1.7M
- First Form D · Jun 2022
- $3.8M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 18 peers
Line = medianBiotech · Device
- Federal grants#1 · top 6%
- Granted patents#4 · top 22%
- Linked publications#1 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Qi ZhaoResearcherExecutive Officer, DirectorLinked by 1 patent · $2.1M in grants as PI
- Christopher McLeodDirectorNamed in SEC Form D filings
- Cynthia GreenDirectorNamed in SEC Form D filings
- Daniel WagnerDirectorNamed in SEC Form D filings
- Dong WangExecutive Officer, DirectorNamed in SEC Form D filings
- Jay TeichDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 4- GrantedSystem And Method To Select And Isolate Particles And Cells And Uses ThereofUSPTOUS 12,209,945
- PendingDestructible Microwell Arrays For Particle Separation And AnalysisUSPTOApplication 18285723
- PendingMethods Of Reducing Noise And Ambiguity In Single Cell AnalysisUSPTOApplication PCTUS2023024917
Show all 4 patent records
- System And Method To Select And Isolate Particles And Cells And Uses ThereofJan 28, 2025 · US 12,209,945Granted
- Destructible Microwell Arrays For Particle Separation And AnalysisJun 13, 2024 · Application 18285723Pending
- Methods Of Reducing Noise And Ambiguity In Single Cell AnalysisApplication PCTUS2023024917Pending
- Destructible Microwell Arrays For Particle Separation And AnalysisApplication PCTUS2022026955Pending
Recent research by its founders
- Periodontitis Phenotypes and Treatment Outcomes Following Combined Periodontal and Orthodontic Therapy: A Cohort Study20261 cites
- Electron acceptor motif-manipulated NIR-II AIE photosensitizers synergically induce tumor pyroptosis through multimodal image-guided pure type I photodynamic and photothermal therapy202518 cites
- Novel microbially transformed bile acids: Biosynthesis, structure, and function202518 cites
Related companies, and why
- Stemgent, Inc.Similar federal contract value in Biotech · $400K in contracts
- RIPTIDE THERAPEUTICS LLCSimilar federal contract value in Biotech · $400K in contracts
- TRITERPENOID THERAPEUTICS INCSimilar federal contract value in Biotech · $400K in contracts
- CYTOBIOSCIENCE INCSimilar federal contract value in Biotech · $387K in contracts
- SIGNABLOK, INC.Similar federal contract value in Biotech · $370K in contracts
- NUVOX PHARMA, L.L.C.Similar federal contract value in Biotech · $356K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .